Zimmer Biomet (NYSE: ZBH) executive earns 4,843 performance-based RSUs

Rhea-AI Filing Summary

Zimmer Biomet Holdings reported that Group President, EMEA, Wilfred Van Zuilen acquired 4,843 restricted stock units (RSUs) as an equity award. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock. These RSUs were earned based on performance for the 2023–2025 period, as determined on February 19, 2026, and are scheduled to vest on March 6, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VAN ZUILEN WILFRED

(Last) (First) (Middle)

345 E. MAIN STREET

(Street)

WARSAW IN 46580

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZIMMER BIOMET HOLDINGS, INC. [ ZBH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Group Pres, EMEA

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/19/2026		A		4,843(2)		03/06/2026	03/06/2026	Common Stock	4,843(2)	$0	4,843	D

Explanation of Responses:

1. Each RSU represents a contingent right to receive one share of Company common stock.

2. On March 6, 2023, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2023 - 2025. As determined on February 19, 2026, based on actual performance, the reporting person earned 4,843 RSUs, which will vest on March 6, 2026.

	/s/ Matthew R. St. Louis, Attorney-in-Fact for Wilhelmus van Zuilen (power of attorney previously filed)	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ZIMMER BIOMET (ZBH) report for Wilfred Van Zuilen?

Zimmer Biomet reported that Group President, EMEA, Wilfred Van Zuilen acquired 4,843 restricted stock units. These RSUs were earned as a performance-based equity award and will convert into common shares upon vesting, aligning his compensation with company performance.

How many restricted stock units did the ZBH executive receive in this Form 4?

The executive received 4,843 restricted stock units. Each RSU represents a right to receive one share of Zimmer Biomet common stock upon vesting, providing stock-based compensation tied to the company’s future share value and long-term performance.

What performance period applied to the 4,843 RSUs reported by ZBH?

The 4,843 RSUs were tied to a performance period covering 2023 through 2025. The number of RSUs earned was determined based on how certain performance conditions were met over that multi-year timeframe, linking the award directly to measured business outcomes.

When were the performance-based RSUs for ZBH’s Wilfred Van Zuilen determined and when will they vest?

The RSUs were determined on February 19, 2026, based on actual performance for 2023–2025. The earned 4,843 RSUs are scheduled to vest on March 6, 2026, at which point they can deliver common shares to the executive.

What does each restricted stock unit represent in the ZIMMER BIOMET Form 4?

Each restricted stock unit represents a contingent right to receive one share of Zimmer Biomet common stock. The units themselves are not shares until they vest, at which time they can settle in company stock for the reporting executive.

Was there a purchase price for the 4,843 RSUs reported by ZBH?

No cash purchase price was reported for the 4,843 RSUs, which carried a transaction price per unit of 0.0000. This indicates the equity was granted as part of compensation rather than bought on the open market by the executive.